MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (16)
2021
-
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study
British Journal of Haematology, Vol. 192, Núm. 1, pp. 82-99
-
Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
Blood Advances, Vol. 5, Núm. 24, pp. 5588-5598
2019
-
Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation (Bone Marrow Transplantation, (2019), 54, 7, (1133-1137), 10.1038/s41409-018-0422-z)
Bone Marrow Transplantation
-
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy
Hematology/ Oncology and Stem Cell Therapy, Vol. 12, Núm. 4, pp. 194-203
-
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
The Lancet, Vol. 393, Núm. 10168, pp. 229-240
-
Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation
2018
-
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment
Hematological Oncology, Vol. 36, Núm. 5, pp. 765-772
-
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: A long-term follow-up analysis from the Spanish GELTAMO registry
Bone Marrow Transplantation
2017
-
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 10, pp. 1631-1640
-
Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Cancer Medicine, Vol. 6, Núm. 12, pp. 2766-2774
-
Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome
Hematological Oncology, Vol. 35, Núm. 4, pp. 520-527
2016
-
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients
Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84
2014
-
Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: A multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study
British Journal of Haematology, Vol. 164, Núm. 5, pp. 668-674
2013
-
Incidence Of Chemotherapy-Induced Neutropenia And Current Practice Of Prophylaxis With Granulocyte Colony-Stimulating Factors In Cancer Patients In Spain: A prospective, observational study
European Journal of Cancer Care, Vol. 22, Núm. 4, pp. 513-521
2003
-
Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation
Haematologica, Vol. 88, Núm. 11, pp. 1272-1278
-
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
Blood, Vol. 102, Núm. 8, pp. 3043-3051